News

Mirador Therapeutics has secured worldwide development and commercialization rights to KP-301, an experimental long-acting antibody therapy licensed from Kira Pharmaceuticals, and plans to develop it for ANCA-associated vasculitis (AAV). KP-301 is a long-acting antibody that blocks C5a, a protein in the complement system that helps drive inflammation and small…

Kidney biopsy findings may help identify which adults with severe kidney involvement due to ANCA-associated vasculitis (AAV) are more likely to recover kidney function after treatment, a small study suggests. Data showed that patients with better kidney function at one year had a higher percentage of normal glomeruli —…

Hearing loss is common among people with two types of ANCA-associated vasculitis (AAV), affecting half of those assessed in a small study in Saudi Arabia, according to researchers. Following audiological and other assessments, the team found loss of hearing in about 50% of participants with granulomatosis with polyangiitis (GPA)…

A study linked higher blood levels of tiny sacs carrying immune proteins from the complement system — which is known to contribute to ANCA-associated vasculitis (AAV) — to kidney involvement and damage in AAV patients. The findings could help doctors detect kidney disease in people with AAV and develop…

The U.S. Food and Drug Administration (FDA) has cleared the start of clinical testing of FT839, Fate Therapeutics’ experimental off-the-shelf CAR T-cell therapy for ANCA-associated vasculitis (AAV) and other autoimmune disorders. The company plans to launch a basket Phase 1/2 clinical trial to evaluate FT839 in combination with…

Blood cell ratios derived from routine blood tests may help distinguish people with active ANCA-associated vasculitis (AAV) from those in glucocorticoid-free remission, independent of age and sex, according to a new study. “Our findings suggested that these readily available, standardized, low-cost biomarkers make them attractive candidates for integration into…

Black people with ANCA-associated vasculitis (AAV) were diagnosed at a younger age than white people and tended to show more signs of kidney disease severity, according to a study in the U.S. “These findings suggest that [variability] in disease presentation within the spectrum of AAV highlights the importance of examining…

Following regulatory attempts in Europe to revoke approval of its ANCA-associated vasculitis (AAV) therapy Tavneos (avacopan), developer Inflarx is now looking to advance two new treatments — both being tested in clinical trials — for this group of autoimmune diseases. The biopharmaceutical company said in a…

A committee of the European Medicines Agency has recommended revoking the marketing authorization for Tavneos (avacopan) — an approved oral therapy for ANCA-associated vasculitis (AAV) — in the European Union (EU) over questions about the drug’s effectiveness data. The recommendation, from the Committee for Medicinal Products for…

People with eosinophilic granulomatosis with polyangiitis (EGPA) waited a median of nearly four years from their first recorded major sign of the disease to diagnosis, and most received prescriptions for oral glucocorticoids and/or immunosuppressants, a real-world study in England shows. Also, in a 486-patient group followed from diagnosis, more…